TH215

Authors: Suzana Bojic ¹, Ruth Zaslansky ², Winfried Meissner ², Ulrike M. Stamer ³, Philipp Baumbach ², <u>Dusica Stamenkovic ⁴</u> ¹ University Clinical Hospital Centre"Dr. Dragisa Misovic – Dedinje", University of Bern, Switzerland; ³ Inselspital, Bern University Hospital, University of Bern, Switzerland; ¹ University Hospital Jena, Friedrich Schiller University, Jena, Germany; ³ Inselspital, Bern University Hospital, University of Bern, Switzerland; ¹ ⁴ Dept. of Anesthesiology and Intensive Care, Military Medical Academy, Medical Faculty University of Defense, Belgrade, Serbia

Background

- The choice of route for administering postoperative analgesia affects its efficacy and cost-effectiveness, as well as patient comfort.
- Current guidelines on postoperative care prioritize the oral route (PO) over intravenous (IV), due to its convenience, non-invasiveness, costeffectiveness while maintaining comparable efficacy.
- The intramuscular route (IM) is discouraged.
- Immediate-release opioids are modified-release favored over formulations [1-4].

Aim

- To evaluate whether clinical practice aligns with current guidelines regarding routes of postoperative analgesia administration.
- To explore the economic implications of any potential misalignment.

Methods

- A secondary analysis of data collected using the PAIN OUT methodology in 10 Serbian hospitals [5].
- 2,354 adult pts who underwent various surgical procedures.
- Pts were followed-up during their stay in surgical wards for the initial 24 hours after surgery.
- We analyzed the proportion of patients receiving non-opioid and opioid analgesics via the PO, IV, and IM routes in the entire cohort and in a subgroup of patients in whom administration of analgesics via PO route was deemed feasible.
- The PO route was not considered feasible patients in undergoing pancreatic gastrointestinal, and hepatobiliary for except surgery laparoscopic cholecystectomy.
- We estimated the projected savings if the PO route was utilized instead of the IV or IM, in a subgroup of pts in whom PO route was feasible.
- Costs of analgesic therapy accounted for the medications, related disposables and staff labor.

References

2. (NICE) NIFHACE. Perioperative care in adults [N1] Evidence reviews for managing acute postoperative pain [NG180]., 2020. 3.Aubrun F, Nouette-Gaulain K, Fletcher D, et al. Revision of expert panel's guidelines on postoperative pain management. Anaesth Crit Care Pain Med 2019; 38: 405-11. 4.Schug SA, Palmer GM, Scott DA, Alcock M HR, Mott JF, College WGotAaNZ. Acute Pain Management: Scientific Evidence. Melbourne: ANZCA & FPM, 2020. 5.Stamenkovic D, Baumbach P, Radovanovic D, et al. The Perioperative Pain Management Bundle is Feasible: Findings From the PAIN OUT Registry. Clin J Pain 2023; 39: 537-45.s

Routes of Administering Analgesics Postoperatively: Practice vs Guidelines & Economic Implications

Results

Analgesia administration routes in the entire cohort

- IV route was utilized for administering non-opioids in 2,043 (87%) pts and opioids in 917 (39%) pts.
- IM route was employed in 156 (7%) pts for nonopioids and 91 (4%) pts for opioids.
- Ten (1%) pts received oral analgesics, all as immediate-release formulations.

Analgesia administration routes in pts with feasible PO route

- PO route was deemed feasible in 1,759 pts.
- IV route was employed in 1,512 (86%) pts for nonopioids and 649 (37%) pts for opioids.
- 129 (7%) pts received IM injections of nonopioids and 86 (5%) of opioids.

Table 1. Parenterally administered analgesics in patients with feasible PO route.

	Intramuscular		Intravenous						
	Number of patients	Number of injections	Number of patients	Number of injections					
Non-opioids									
Ketorolac	1 (0.1%)	2	435 (23.5%)	789					
Paracetamol	NA	NA	579 (30.9%)	670					
Diclofenac	124 (6.7%)	162	251 (13.6%)	342					
Metamizole	9 (0.5%)	24	677 (36.6%)	399					
Ketoprofen	11 (0.6%)	18	93 (5.0%)	130					
Opioids									
Tramadol	58 (3.1%)	83	558 (30.2%)	1369					
Morphine	12 (0.6%)	12	141 (7.6%)	142					
Pethidine	17 (0.9%)	26	11 (0.6%)	13					

Table 2. Costs and projected cost reduction in surgical patients with feasible PO route.

Surgical Discipline	Number of patients	Cost of IV and IM analgesics		Projected cost of PO analgesics		Projected cost reduction (%)
		RSD	USD	RSD	USD	
Cardiac	228	192,877.2	1,839.55	24,970.5	238.15	87.1
General	603	345,424.8	3,294.47	78,521.7	748.90	77.3
Obstetrics & gynecology	344	171,425.2	1,634.96	49,981.1	476.69	70.8
Traumatology & Orthopedics	475	467,495.3	4,458.71	50,952.6	485.96	89.1
Urology	202	343,975.8	3,280.65	25,819.9	246.26	92.5
Sum	1850	1,521,198.3	14,508.33	230,245.8	2195.96	84.9

- Projected savings averaged at 85%.

Conclusion

- analgesics.



• Costs of parenteral analgesics averaged at 822.3 RSD (7.94 USD) per patient. • Average projected costs of oral analgesics were 124.5 RSD (1.19 USD) per patient.

• Our findings reveal a widespread reliance on IV administration for postoperative

• The limited use of oral analgesics, especially in eligible pts, underscores a notable disparity between practice and guidelines.

• The prevalence of the IM route is cause for concern.

• Substantial projected cost savings associated with oral analgesics highlights the importance of aligning practice with evidence-based recommendations.

^{1.} Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain 2016; 17: 131-